Cambridge Antibody: R&D update

In its summer 2000 CAT News, Cambridge Antibody Technology notes that ithas four fully-human monoclonal antibodies in clinical trials, more than any other company developing such products. The four are:

- D2E7, TNF-alpha, for the treatment of rheumatoid arthritis, which started Phase III clinical trials in February this year with partner BASF Pharma;

- CAT-152, TGF-beta2, for use in glaucoma surgery, which entered Phase II testing in October 1999;